Evidence mapPaperPMID 41378205Full record

ReviewFrontiers in pharmacology2025

Therapeutic efficacy and mechanisms of gentiopicroside in various diseases.

Ling Kui, Guoyun Wang, Jinqun Huang, Xiaonan Yang, Jinshi Yu, Xi Li, Huaming Peng, Bingfeng Leng, Yinming Jiao, Zhanjiang Zhang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Development of Wedelia (Current issues in molecular biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ling Kui *Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Guoyun Wang *Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Jinqun HuangFunctional Microbiology R&D Center, Research Institute of Tsinghua University in Shenzhen, Shenzhen, China.
Xiaonan YangNational Engineering Research Center for Southwest Endangered Medicinal Resources Development, Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Jinshi YuShenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Xi LiShenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Huaming PengShenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Bingfeng LengFunctional Microbiology R&D Center, Research Institute of Tsinghua University in Shenzhen, Shenzhen, China.
Yinming JiaoShenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Zhanjiang ZhangGuangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gentiopicroside (GPS), a secoiridoid glycoside found in traditional medicinal plants such as Gentiana scabra Bunge, exhibits diverse pharmacological properties, including anti-inflammatory, antioxidant, neuroprotective, hepatoprotective, antidiabetic, antitumor, and skin disease-modulating effects. This review consolidates current research on GPS, highlighting its mechanisms of action across various diseases. GPS modulates key signaling pathways, such as NF-κB and MAPK, to suppress pro-inflammatory cytokines and oxidative stress. It activates the Keap1-Nrf2 pathway to enhance cellular antioxidant defenses and exhibits direct free radical scavenging capabilities. In neurodegenerative diseases like Alzheimer's and Parkinson's, GPS reduces amyloid-β accumulation and dopaminergic neuron loss, respectively. Its hepatoprotective effects include mitigating chemical- and alcohol-induced liver damage by regulating lipid metabolism and reducing fibrosis. GPS also improves insulin sensitivity in diabetes and inhibits tumor cell proliferation and migration. Additionally, GPS shows promise in treating skin conditions like psoriasis and enhancing wound healing. Despite its therapeutic potential, current evidence is limited by methodological gaps, preclinical inconsistencies and weak clinical evidence (no large-scale randomized controlled trials [RCTs]). Challenges such as low bioavailability and the need for further clinical validation remain. Future research should focus on optimizing GPS formulations and conducting rigorous RCTs, standardizing botanical drug characterization, translating preclinical findings into effective therapies.

Indexed as

drug developmentgentiopicrosidepharmacological mechanismstherapeutic applicationstraditional medicine

Identifiers

PMID41378205
PMCPMC12685940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.